CD274 and cancer: Recently, targeting B7-H3 (PD-L3; CD274), a member of the PD-L1 family, as well as Myeloid Derived Suppressor cells (MDSCs), has been demonstrated to overcome immunosuppression in CRPC, and other cancer types, in preclinical models [225,226].